Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany

Elena Rivero-Ferrer*, Morten Olesen, Estel Plana, Jaume Aguado, Núria Saigí-Morgui, Annalisa Rubino, Sami Z. Daoud, Alejhandra Lei, Susana Perez-Gutthann, Tania Schink, Nina Sahlertz Kristiansen, Jesper Hallas, Anton Pottegård, Cristina Rebordosa

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

6 Downloads (Pure)

Abstract

Background and Objectives: Aclidinium bromide was approved in the European Union for the treatment of chronic obstructive pulmonary disease (COPD) in adult patients in 2012 and in a fixed-dose combination with formoterol in 2014. We characterised new users of aclidinium, aclidinium/formoterol and other COPD medications and evaluated off-label prescribing of these medications in three European populations. Methods: We described demographic characteristics, comorbidities, comedications, COPD severity and off-label prescribing of new users of aclidinium, aclidinium/formoterol and other COPD medications in patients with COPD aged ≥ 40 years in the Clinical Practice Research Datalink (CPRD, UK), Danish National Health Databases, and German Pharmacoepidemiological Research Database (GePaRD) between 2015 and 2017. Results: We included 17,668 new users of aclidinium (CPRD, 4871; Denmark, 2836; GePaRD, 9961) and 14,808 new users of aclidinium/formoterol (CPRD, 2153; Denmark, 2586; GePaRD, 10,069). Study patients were of similar age, except in GePaRD, where users of long-acting beta2-agonists (LABA)/inhaled corticosteroids were younger. Patients had multiple comorbidities and used multiple comedications—most frequently hypertension (50–79%) and short-acting beta2-agonists (26–84%). Aclidinium users in CPRD and long-acting anticholinergics/LABA users in Denmark and GePaRD had the highest frequency of severe/very severe COPD. Off-label prescribing of aclidinium (5.0% [CPRD]–8.9% [Denmark]) and aclidinium/formoterol (2.6% [GePaRD]–3.2% [CPRD]) was low, and the main reason was asthma without a COPD diagnosis. Conclusions: Aclidinium and aclidinium/formoterol were mostly prescribed according to label, with preference given to older patients with more severe COPD and to patients with a high prevalence of comorbidities and comedication use.

Original languageEnglish
JournalClinical Drug Investigation
Volume42
Issue number4
Pages (from-to)319-331
ISSN1173-2563
DOIs
Publication statusPublished - Apr 2022

Keywords

  • Administration, Inhalation
  • Adrenergic beta-2 Receptor Agonists/therapeutic use
  • Adult
  • Bronchodilator Agents
  • Denmark
  • Formoterol Fumarate
  • Humans
  • Muscarinic Antagonists/therapeutic use
  • Pulmonary Disease, Chronic Obstructive/diagnosis
  • Tropanes/adverse effects
  • United Kingdom/epidemiology

Fingerprint

Dive into the research topics of 'Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany'. Together they form a unique fingerprint.

Cite this